查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1926307

感染疾病體外診斷市場：全球產業分析、規模、佔有率、成長、趨勢與預測（2025-2044）

Infectious Disease In-vitro Diagnostics Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025-2044
出版日期: | 出版商: Persistence Market Research | 英文 188 Pages | 商品交期: 2-5個工作天內

價格
簡介目錄

主要發現：

  • 感染疾病體外診斷市場規模（2025年預測）：466億美元
  • 預計市場規模（2032年）：641億美元
  • 全球市場成長率（2025年至2032年複合年成長率）：4.7%

感染疾病體外診斷市場研究範圍：

感染疾病體外診斷 (IVD) 解決方案在感染疾病的檢測、監測和管理中發揮著至關重要的作用，其應用方式包括實驗室檢測和體外就地檢驗。這些診斷方法對於識別病原體（例如細菌、病毒、真菌和寄生蟲）至關重要，這些病原體可導致愛滋病、肝炎、流感、結核病、瘧疾和新出現的病毒感染疾病等疾病。該市場服務於醫院、診斷檢查室、診所和分散式醫療機構，並採用分子診斷、免疫檢測和快速檢測套組等技術。日益加重的全球疾病負擔、對早期準確診斷不斷成長的需求以及診斷技術的進步（使得檢測速度更快、更可靠）正在推動市場擴張。

市場成長要素：

全球感染疾病體外診斷市場受多種關鍵因素驅動，包括全球感染疾病率的不斷上升以及為防止疾病傳播而日益成長的快速疾病檢測需求。醫療基礎設施和檢測能力的不斷成長，尤其是在新興經濟體，進一步推動了市場需求。 PCR 檢測、次世代定序以及快速抗原和分子檢測等技術進步顯著提高了檢測準確性和周轉時間。此外，在分散式環境中就地檢驗設備的日益普及以及旨在控制和預防疾病的公共衛生舉措也持續推動市場成長。近期全球疫情的爆發提高了人們的防範意識，也促進了全球診斷準備和監測系統的加強。

市場限制：

儘管感染疾病體外診斷市場前景強勁，但仍面臨諸多挑戰，例如診斷設備高成本、監管要求嚴格、報銷機制不一致。遵守監管核准和品質標準增加了營運複雜性，並延緩了產品上市。低收入地區醫療基礎設施的匱乏和經濟負擔限制了先進診斷解決方案的廣泛應用。此外，對檢測準確性、假陽性和假陰性的擔憂，以及對熟練實驗室技術人員的需求，也是市場擴張的障礙。應對這些挑戰需要醫療機構、製造商和政策制定者之間的合作，以確保診斷的可近性和可靠性。

市場機會：

在技​​術創新和不斷發展的醫療服務模式的推動下，感染疾病體外診斷市場展現出巨大的成長潛力。攜帶式快速診斷設備的研發使得在偏遠和資源匱乏地區開展檢測成為可能，從而改善了醫療服務的可及性。數位健康平台、人工智慧驅動的診斷工具和數據分析的整合，增強了疾病監測和疫情應對能力。抗菌素抗藥性檢測和個人化醫療等領域的應用拓展也拓寬了市場前景。對於希望在充滿活力的感染疾病診斷領域把握未來成長機會的企業而言，策略合作、研發投入以及推出經濟高效且易於使用的檢測解決方案至關重要。

本報告解答的關鍵問題：

  • 推動全球感染疾病體外診斷市場成長的關鍵因素有哪些？
  • 哪些類型的技術和檢測方法正在推動醫療保健領域的應用？
  • 技術進步如何改變感染疾病診斷市場的競爭格局？
  • 哪些公司是感染疾病診斷市場的主要企業貢獻者？它們正在採取哪些策略來維持其市場地位？
  • 全球感染疾病體外診斷市場有哪些新興趨勢與未來前景？

目錄

第1章執行摘要

第2章 市場概覽

  • 市場範圍和定義
  • 市場動態
    • 促進要素
    • 抑制因素
    • 機會
    • 任務
    • 主要趨勢
  • 宏觀經濟因素
  • 新冠疫情影響分析
  • 預測因子－相關性和影響

第3章 加值見解

  • 監管狀態
  • 產品導入分析
  • 價值鏈分析
  • 重大交易和合併
  • PESTLE分析
  • 波特五力分析

第4章 全球感染疾病體外診斷市場展望：

  • 主要亮點
    • 市場規模和年成長率
    • 絕對商機
  • 市場規模分析與預測
    • 2019-2024年市場規模績效分析
    • 目前市場規模分析及預測（2025-2032年）
  • 全球感染疾病體外診斷市場依產品類型展望
    • 引言/主要發現
    • 2019-2024年按產品類型分類的市場規模表現分析
    • 依產品類型分類的當前市場規模分析及預測（2025-2032年）
      • 裝置
      • 試劑
      • 軟體和服務
    • 按產品類型分類的市場吸引力分析
  • 全球感染疾病體外診斷技術市場展望
    • 引言/主要發現
    • 按技術分類的市場規模績效分析，2019-2024 年
    • 按技術分類的當前市場規模分析和預測（2025-2032 年）
      • 免疫檢測
      • 分子診斷
      • 微生物學
      • 其他
    • 技術市場吸引力分析
  • 全球感染疾病體外診斷市場展望（依應用領域分類）
    • 引言/主要發現
    • 按應用領域分類的市場規模績效分析（2019-2024 年）
    • 按應用領域分類的當前市場規模分析及預測（2025-2032 年）
      • MRSA
      • 困難梭狀芽孢桿菌
      • 呼吸道病毒
      • 結核病和抗藥性結核病
      • 淋病
      • 人類乳突病毒
      • HIV
      • C型肝炎
      • B型肝炎
      • COVID-19
      • 其他
    • 按應用領域進行市場吸引力分析
  • 全球感染疾病體外診斷市場展望：終端用戶
    • 引言/主要發現
    • 按最終用戶分類的市場規模績效分析，2019-2024 年
    • 按最終用戶分類的當前市場規模分析及預測（2025-2032 年）
      • 照護現場
      • 中心檢查室
      • 其他
    • 最終用戶市場吸引力分析

第5章 全球感染疾病體外診斷市場區域展望

  • 主要亮點
  • 2019-2024年各地區市場規模表現分析
  • 目前市場規模分析及預測（按地區分類，2025-2032年）
    • 北美洲
    • 歐洲
    • 東亞
    • 南亞和大洋洲
    • 拉丁美洲
    • 中東和非洲
  • 按地區分類的市場吸引力分析

第6章 北美感染疾病體外診斷市場展望：

第7章 歐洲感染疾病體外診斷市場展望：

第8章 東亞感染疾病體外診斷市場展望：

第9章 南亞和大洋洲感染疾病體外診斷市場展望：

10. 拉丁美洲感染疾病體外診斷市場展望

第11章：中東和非洲感染疾病體外診斷市場展望

第12章 競爭格局

  • 2024年市佔率分析
  • 市場結構
    • 按市場分類的競爭強度程度
    • 競爭對手儀錶板
  • 公司簡介（詳情 - 概述、財務狀況、策略、近期發展）
    • QIAGEN
    • Becton, Dickinson and Company
    • bioMerieux SA
    • F. Hoffmann-La Roche, Ltd.
    • Hologic, Inc.（Gen Probe）
    • Abbott
    • Quidel Corporation
    • Siemens Healthineers AG
    • Bio-Rad Laboratories, Inc.
    • Danaher
    • OraSure Technologies, Inc.
    • Others

第13章附錄

簡介目錄
Product Code: PMRREP33205

Persistence Market Research has recently released a comprehensive report on the worldwide market for infectious disease in-vitro diagnostics. The report offers a thorough assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, providing detailed insights into the market structure. This research publication presents exclusive data and statistics outlining the anticipated growth trajectory of the global infectious disease in-vitro diagnostics market from 2025 to 2032. The infectious disease in-vitro diagnostics market is positioned for significant growth, with a projected CAGR of 4.7% from 2025 to 2032, indicating a market value increase from USD 46.6 billion in 2025 to USD 64.1 billion by 2032.

Key Insights:

  • Infectious Disease In-vitro Diagnostics Market Size (2025E): USD 46.6 Bn
  • Projected Market Value (2032F): USD 64.1 Bn
  • Global Market Growth Rate (CAGR 2025 to 2032): 4.7%

Infectious Disease In-vitro Diagnostics Market - Report Scope:

Infectious disease in-vitro diagnostics (IVD) solutions play a critical role in detecting, monitoring, and managing infectious diseases through laboratory-based or point-of-care testing outside the human body. These diagnostics are essential in identifying pathogens such as bacteria, viruses, fungi, and parasites responsible for diseases including HIV, hepatitis, influenza, tuberculosis, malaria, and emerging viral infections. The market caters to hospitals, diagnostic laboratories, clinics, and decentralized healthcare settings with technologies such as molecular diagnostics, immunoassays, and rapid testing kits. Market expansion is fueled by rising global disease burden, increasing demand for early and accurate diagnosis, and advancements in diagnostic technologies enabling faster and more reliable testing.

Market Growth Drivers:

The global infectious disease in-vitro diagnostics market is propelled by several key factors, including the growing incidence of infectious diseases worldwide and the rising need for rapid disease detection to prevent outbreaks. Increasing investments in healthcare infrastructure and laboratory capacity, especially in emerging economies, further accelerate market demand. Technological advancements such as PCR-based diagnostics, next-generation sequencing, and rapid antigen and molecular tests have significantly improved detection accuracy and turnaround times. Additionally, the growing use of point-of-care testing devices in decentralized settings and public health initiatives aimed at disease control and prevention continue to drive market growth. Heightened awareness following recent global pandemics has also strengthened diagnostic preparedness and surveillance systems worldwide.

Market Restraints:

Despite strong growth prospects, the infectious disease IVD market faces challenges associated with high diagnostic equipment costs, stringent regulatory requirements, and variability in reimbursement frameworks. Compliance with regulatory approvals and quality standards increases operational complexity and delays product launches. Limited healthcare infrastructure and affordability challenges in low-income regions restrict widespread adoption of advanced diagnostic solutions. Furthermore, concerns regarding test accuracy, false positives or negatives, and the need for skilled laboratory personnel also present obstacles to market expansion. Addressing these challenges requires coordinated efforts among healthcare authorities, manufacturers, and policymakers to ensure accessible and reliable diagnostics.

Market Opportunities:

The infectious disease in-vitro diagnostics market presents promising growth opportunities driven by technological innovation and evolving healthcare delivery models. The development of portable and rapid diagnostic devices enables testing in remote and resource-limited settings, improving access to healthcare services. Integration of digital health platforms, AI-driven diagnostic tools, and data analytics enhances disease monitoring and outbreak response capabilities. Expanding applications in antimicrobial resistance detection and personalized medicine also broaden market prospects. Strategic partnerships, investments in research and development, and the launch of cost-effective and user-friendly testing solutions will be critical for companies seeking to capitalize on future growth opportunities in the dynamic infectious disease diagnostics landscape.

Key Questions Answered in the Report:

  • What are the primary factors driving the growth of the infectious disease in-vitro diagnostics market globally?
  • Which technologies and test types are driving adoption across healthcare settings?
  • How are technological advancements reshaping the competitive landscape of the infectious disease diagnostics market?
  • Who are the key players contributing to the infectious disease IVD market, and what strategies are they employing to maintain market relevance?
  • What are the emerging trends and future prospects in the global infectious disease in-vitro diagnostics market?

Competitive Intelligence and Business Strategy:

Leading players in the global infectious disease in-vitro diagnostics market, including Roche Diagnostics, Abbott Laboratories, and Thermo Fisher Scientific, focus on technological innovation, portfolio expansion, and strategic collaborations to maintain competitive advantage. Companies continue investing heavily in molecular diagnostic technologies and rapid testing platforms to meet growing global demand for accurate and timely detection. Partnerships with healthcare providers and government health agencies support widespread test deployment and improve access to diagnostics. Additionally, companies emphasize automation, digital integration, and scalable testing solutions to enhance laboratory efficiency and clinical outcomes in an increasingly dynamic healthcare environment.

Key Companies Profiled:

  • QIAGEN
  • Becton, Dickinson and Company
  • bioMerieux SA
  • F. Hoffmann-La Roche, Ltd.
  • Hologic, Inc. (Gen Probe)
  • Abbott
  • Quidel Corporation
  • Siemens Healthineers AG
  • Bio-Rad Laboratories, Inc.
  • Danaher
  • OraSure Technologies, Inc.

Infectious Disease In-vitro Diagnostics Industry Segmentation

By Product Type

  • Instruments
  • Reagents
  • Software and Services

By Technology

  • Immunoassay
  • Molecular Diagnostics
  • Microbiology
  • Others

By Application

  • MRSA
  • Clostridium Difficile
  • Respiratory Virus
  • TB and Drug-resistant TB
  • Gonorrhea
  • HPV
  • HIV
  • Hepatitis C
  • Hepatitis B
  • COVID-19
  • Others

By End User

  • Point-of-care
  • Central Laboratories
  • Others

By Region

  • North America
  • Europe
  • East Asia
  • South Asia and Oceania
  • Latin America
  • Middle East and Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Infectious Disease In-vitro Diagnostics Market Snapshot, 2025 and 2032
  • 1.2. Market Opportunity Assessment, 2025-2032, US$ Bn
  • 1.3. Key Market Trends
  • 1.4. Future Market Projections
  • 1.5. Premium Market Insights
  • 1.6. Industry Developments and Key Market Events
  • 1.7. PMR Analysis and Recommendations

2. Market Overview

  • 2.1. Market Scope and Definition
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Opportunity
    • 2.2.4. Challenges
    • 2.2.5. Key Trends
  • 2.3. Macro-Economic Factors
    • 2.3.1. Global Sectorial Outlook
    • 2.3.2. Global GDP Growth Outlook
  • 2.4. COVID-19 Impact Analysis
  • 2.5. Forecast Factors - Relevance and Impact

3. Value Added Insights

  • 3.1. Regulatory Landscape
  • 3.2. Product Adoption Analysis
  • 3.3. Value Chain Analysis
  • 3.4. Key Deals and Mergers
  • 3.5. PESTLE Analysis
  • 3.6. Porter's Five Force Analysis

4. Global Infectious Disease In-vitro Diagnostics Market Outlook:

  • 4.1. Key Highlights
    • 4.1.1. Market Size (US$ Bn) and Y-o-Y Growth
    • 4.1.2. Absolute $ Opportunity
  • 4.2. Market Size (US$ Bn) Analysis and Forecast
    • 4.2.1. Historical Market Size (US$ Bn) Analysis, 2019-2024
    • 4.2.2. Current Market Size (US$ Bn) Analysis and Forecast, 2025-2032
  • 4.3. Global Infectious Disease In-vitro Diagnostics Market Outlook: Product Type
    • 4.3.1. Introduction / Key Findings
    • 4.3.2. Historical Market Size (US$ Bn) Analysis, By Product Type, 2019-2024
    • 4.3.3. Current Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2025-2032
      • 4.3.3.1. Instruments
      • 4.3.3.2. Reagents
      • 4.3.3.3. Software and Services
    • 4.3.4. Market Attractiveness Analysis: Product Type
  • 4.4. Global Infectious Disease In-vitro Diagnostics Market Outlook: Technology
    • 4.4.1. Introduction / Key Findings
    • 4.4.2. Historical Market Size (US$ Bn) Analysis, By Technology, 2019-2024
    • 4.4.3. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2025-2032
      • 4.4.3.1. Immunoassay
      • 4.4.3.2. Molecular Diagnostics
      • 4.4.3.3. Microbiology
      • 4.4.3.4. Others
    • 4.4.4. Market Attractiveness Analysis: Technology
  • 4.5. Global Infectious Disease In-vitro Diagnostics Market Outlook: Application
    • 4.5.1. Introduction / Key Findings
    • 4.5.2. Historical Market Size (US$ Bn) Analysis, By Application, 2019-2024
    • 4.5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
      • 4.5.3.1. MRSA
      • 4.5.3.2. Clostridium Difficile
      • 4.5.3.3. Respiratory Virus
      • 4.5.3.4. TB and Drug-resistant TB
      • 4.5.3.5. Gonorrhea
      • 4.5.3.6. HPV
      • 4.5.3.7. HIV
      • 4.5.3.8. Hepatitis C
      • 4.5.3.9. Hepatitis B
      • 4.5.3.10. COVID-19
      • 4.5.3.11. Others
    • 4.5.4. Market Attractiveness Analysis: Application
  • 4.6. Global Infectious Disease In-vitro Diagnostics Market Outlook: End User
    • 4.6.1. Introduction / Key Findings
    • 4.6.2. Historical Market Size (US$ Bn) Analysis, By End User, 2019-2024
    • 4.6.3. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2025-2032
      • 4.6.3.1. Point-of-care
      • 4.6.3.2. Central Laboratories
      • 4.6.3.3. Others
    • 4.6.4. Market Attractiveness Analysis: End User

5. Global Infectious Disease In-vitro Diagnostics Market Outlook: Region

  • 5.1. Key Highlights
  • 5.2. Historical Market Size (US$ Bn) Analysis, By Region, 2019-2024
  • 5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Region, 2025-2032
    • 5.3.1. North America
    • 5.3.2. Europe
    • 5.3.3. East Asia
    • 5.3.4. South Asia and Oceania
    • 5.3.5. Latin America
    • 5.3.6. Middle East & Africa
  • 5.4. Market Attractiveness Analysis: Region

6. North America Infectious Disease In-vitro Diagnostics Market Outlook:

  • 6.1. Key Highlights
  • 6.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 6.2.1. By Country
    • 6.2.2. By Product Type
    • 6.2.3. By Technology
    • 6.2.4. By Application
    • 6.2.5. By End User
  • 6.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
    • 6.3.1. U.S.
    • 6.3.2. Canada
  • 6.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2025-2032
    • 6.4.1. Instruments
    • 6.4.2. Reagents
    • 6.4.3. Software and Services
  • 6.5. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2025-2032
    • 6.5.1. Immunoassay
    • 6.5.2. Molecular Diagnostics
    • 6.5.3. Microbiology
    • 6.5.4. Others
  • 6.6. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
    • 6.6.1. MRSA
    • 6.6.2. Clostridium Difficile
    • 6.6.3. Respiratory Virus
    • 6.6.4. TB and Drug-resistant TB
    • 6.6.5. Gonorrhea
    • 6.6.6. HPV
    • 6.6.7. HIV
    • 6.6.8. Hepatitis C
    • 6.6.9. Hepatitis B
    • 6.6.10. COVID-19
    • 6.6.11. Others
  • 6.7. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2025-2032
    • 6.7.1. Point-of-care
    • 6.7.2. Central Laboratories
    • 6.7.3. Others
  • 6.8. Market Attractiveness Analysis

7. Europe Infectious Disease In-vitro Diagnostics Market Outlook:

  • 7.1. Key Highlights
  • 7.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 7.2.1. By Country
    • 7.2.2. By Product Type
    • 7.2.3. By Technology
    • 7.2.4. By Application
    • 7.2.5. By End User
  • 7.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
    • 7.3.1. Germany
    • 7.3.2. France
    • 7.3.3. U.K.
    • 7.3.4. Italy
    • 7.3.5. Spain
    • 7.3.6. Russia
    • 7.3.7. Rest of Europe
  • 7.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2025-2032
    • 7.4.1. Instruments
    • 7.4.2. Reagents
    • 7.4.3. Software and Services
  • 7.5. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2025-2032
    • 7.5.1. Immunoassay
    • 7.5.2. Molecular Diagnostics
    • 7.5.3. Microbiology
    • 7.5.4. Others
  • 7.6. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
    • 7.6.1. MRSA
    • 7.6.2. Clostridium Difficile
    • 7.6.3. Respiratory Virus
    • 7.6.4. TB and Drug-resistant TB
    • 7.6.5. Gonorrhea
    • 7.6.6. HPV
    • 7.6.7. HIV
    • 7.6.8. Hepatitis C
    • 7.6.9. Hepatitis B
    • 7.6.10. COVID-19
    • 7.6.11. Others
  • 7.7. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2025-2032
    • 7.7.1. Point-of-care
    • 7.7.2. Central Laboratories
    • 7.7.3. Others
  • 7.8. Market Attractiveness Analysis

8. East Asia Infectious Disease In-vitro Diagnostics Market Outlook:

  • 8.1. Key Highlights
  • 8.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 8.2.1. By Country
    • 8.2.2. By Product Type
    • 8.2.3. By Technology
    • 8.2.4. By Application
    • 8.2.5. By End User
  • 8.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
    • 8.3.1. China
    • 8.3.2. Japan
    • 8.3.3. South Korea
  • 8.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2025-2032
    • 8.4.1. Instruments
    • 8.4.2. Reagents
    • 8.4.3. Software and Services
  • 8.5. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2025-2032
    • 8.5.1. Immunoassay
    • 8.5.2. Molecular Diagnostics
    • 8.5.3. Microbiology
    • 8.5.4. Others
  • 8.6. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
    • 8.6.1. MRSA
    • 8.6.2. Clostridium Difficile
    • 8.6.3. Respiratory Virus
    • 8.6.4. TB and Drug-resistant TB
    • 8.6.5. Gonorrhea
    • 8.6.6. HPV
    • 8.6.7. HIV
    • 8.6.8. Hepatitis C
    • 8.6.9. Hepatitis B
    • 8.6.10. COVID-19
    • 8.6.11. Others
  • 8.7. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2025-2032
    • 8.7.1. Point-of-care
    • 8.7.2. Central Laboratories
    • 8.7.3. Others
  • 8.8. Market Attractiveness Analysis

9. South Asia & Oceania Infectious Disease In-vitro Diagnostics Market Outlook:

  • 9.1. Key Highlights
  • 9.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 9.2.1. By Country
    • 9.2.2. By Product Type
    • 9.2.3. By Technology
    • 9.2.4. By Application
    • 9.2.5. By End User
  • 9.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
    • 9.3.1. India
    • 9.3.2. Southeast Asia
    • 9.3.3. ANZ
    • 9.3.4. Rest of South Asia & Oceania
  • 9.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2025-2032
    • 9.4.1. Instruments
    • 9.4.2. Reagents
    • 9.4.3. Software and Services
  • 9.5. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2025-2032
    • 9.5.1. Immunoassay
    • 9.5.2. Molecular Diagnostics
    • 9.5.3. Microbiology
    • 9.5.4. Others
  • 9.6. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
    • 9.6.1. MRSA
    • 9.6.2. Clostridium Difficile
    • 9.6.3. Respiratory Virus
    • 9.6.4. TB and Drug-resistant TB
    • 9.6.5. Gonorrhea
    • 9.6.6. HPV
    • 9.6.7. HIV
    • 9.6.8. Hepatitis C
    • 9.6.9. Hepatitis B
    • 9.6.10. COVID-19
    • 9.6.11. Others
  • 9.7. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2025-2032
    • 9.7.1. Point-of-care
    • 9.7.2. Central Laboratories
    • 9.7.3. Others
  • 9.8. Market Attractiveness Analysis

10. Latin America Infectious Disease In-vitro Diagnostics Market Outlook:

  • 10.1. Key Highlights
  • 10.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 10.2.1. By Country
    • 10.2.2. By Product Type
    • 10.2.3. By Technology
    • 10.2.4. By Application
    • 10.2.5. By End User
  • 10.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
    • 10.3.1. Brazil
    • 10.3.2. Mexico
    • 10.3.3. Rest of Latin America
  • 10.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2025-2032
    • 10.4.1. Instruments
    • 10.4.2. Reagents
    • 10.4.3. Software and Services
  • 10.5. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2025-2032
    • 10.5.1. Immunoassay
    • 10.5.2. Molecular Diagnostics
    • 10.5.3. Microbiology
    • 10.5.4. Others
  • 10.6. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
    • 10.6.1. MRSA
    • 10.6.2. Clostridium Difficile
    • 10.6.3. Respiratory Virus
    • 10.6.4. TB and Drug-resistant TB
    • 10.6.5. Gonorrhea
    • 10.6.6. HPV
    • 10.6.7. HIV
    • 10.6.8. Hepatitis C
    • 10.6.9. Hepatitis B
    • 10.6.10. COVID-19
    • 10.6.11. Others
  • 10.7. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2025-2032
    • 10.7.1. Point-of-care
    • 10.7.2. Central Laboratories
    • 10.7.3. Others
  • 10.8. Market Attractiveness Analysis

11. Middle East & Africa Infectious Disease In-vitro Diagnostics Market Outlook:

  • 11.1. Key Highlights
  • 11.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 11.2.1. By Country
    • 11.2.2. By Product Type
    • 11.2.3. By Technology
    • 11.2.4. By Application
    • 11.2.5. By End User
  • 11.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
    • 11.3.1. GCC Countries
    • 11.3.2. Egypt
    • 11.3.3. South Africa
    • 11.3.4. Northern Africa
    • 11.3.5. Rest of Middle East & Africa
  • 11.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2025-2032
    • 11.4.1. Instruments
    • 11.4.2. Reagents
    • 11.4.3. Software and Services
  • 11.5. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2025-2032
    • 11.5.1. Immunoassay
    • 11.5.2. Molecular Diagnostics
    • 11.5.3. Microbiology
    • 11.5.4. Others
  • 11.6. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
    • 11.6.1. MRSA
    • 11.6.2. Clostridium Difficile
    • 11.6.3. Respiratory Virus
    • 11.6.4. TB and Drug-resistant TB
    • 11.6.5. Gonorrhea
    • 11.6.6. HPV
    • 11.6.7. HIV
    • 11.6.8. Hepatitis C
    • 11.6.9. Hepatitis B
    • 11.6.10. COVID-19
    • 11.6.11. Others
  • 11.7. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2025-2032
    • 11.7.1. Point-of-care
    • 11.7.2. Central Laboratories
    • 11.7.3. Others
  • 11.8. Market Attractiveness Analysis

12. Competition Landscape

  • 12.1. Market Share Analysis, 2024
  • 12.2. Market Structure
    • 12.2.1. Competition Intensity Mapping By Market
    • 12.2.2. Competition Dashboard
  • 12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
    • 12.3.1. QIAGEN
      • 12.3.1.1. Overview
      • 12.3.1.2. Segments and Products
      • 12.3.1.3. Key Financials
      • 12.3.1.4. Market Developments
      • 12.3.1.5. Market Strategy
    • 12.3.2. Becton, Dickinson and Company
    • 12.3.3. bioMerieux SA
    • 12.3.4. F. Hoffmann-La Roche, Ltd.
    • 12.3.5. Hologic, Inc. (Gen Probe)
    • 12.3.6. Abbott
    • 12.3.7. Quidel Corporation
    • 12.3.8. Siemens Healthineers AG
    • 12.3.9. Bio-Rad Laboratories, Inc.
    • 12.3.10. Danaher
    • 12.3.11. OraSure Technologies, Inc.
    • 12.3.12. Others

13. Appendix

  • 13.1. Research Methodology
  • 13.2. Research Assumptions
  • 13.3. Acronyms and Abbreviations